Related Experiment Videos
Intestinal cancer in patients with a germline mutation in the down-regulated in adenoma (DRA) gene
A Hemminki1, P Höglund, E Pukkala
1Department of Medical Genetics, Haartman Institute, University of Helsinki, Finland.
Abstract:
A recent study has revealed that germline mutations of the down-regulated in adenoma (DRA) gene are a likely cause of a recessive intestinal absorption defect, congenital chloride diarrhea. This finding was in accordance with previous works showing that DRA encodes a sodium independent transporter for sulfate and oxalate. Although DRA was originally reported as a candidate tumor suppressor, these studies have questioned the relevance of DRA in cancer. To evaluate whether further studies on the role of DRA in tumorigenesis are still of interest, we examined whether individuals carrying germline DRA mutations have an excess of intestinal cancer. Cancer status of 229 members of 36 Finnish congenital chloride diarrhea families (44 homozygous patients, 70 heterozygous parents, and 115 grandparents at 50% risk of being a DRA mutation carrier) was checked at the Finnish Cancer Registry and the risk of intestinal cancer was found slightly elevated (standardized incidence ratio 3.4, 95% confidence interval 1.4-7.0, P < 0.05). While this result does not unambiguously demonstrate an increased intestinal cancer risk in DRA mutation carriers, it should promote further studies to determine the possible role of DRA in cancer.
Insights
Germline mutations in the down-regulated in adenoma (DRA) gene cause congenital chloride diarrhea. This study found a slightly elevated intestinal cancer risk in individuals with DRA mutations, suggesting further research into its role in tumorigenesis.
Area of Science:
- Genetics
- Gastroenterology
- Oncology
Background:
- Germline mutations in the down-regulated in adenoma (DRA) gene are linked to congenital chloride diarrhea, an intestinal absorption defect.
- Previous research indicated DRA encodes a sulfate and oxalate transporter, but its role as a tumor suppressor in cancer remains uncertain.
Purpose of the Study:
- To investigate whether individuals with germline DRA mutations have an increased risk of developing intestinal cancer.
- To evaluate the relevance of DRA in tumorigenesis and guide future research directions.
Main Methods:
- Cancer status of 229 individuals from 36 Finnish congenital chloride diarrhea families was analyzed using the Finnish Cancer Registry.
- The cohort included homozygous patients, heterozygous parents, and at-risk grandparents with potential DRA mutations.
Main Results:
- A slightly elevated risk of intestinal cancer was observed in the studied population (Standardized Incidence Ratio = 3.4, P < 0.05).
- The findings suggest a potential association between DRA mutations and intestinal cancer, though not definitively proven.
Conclusions:
- While the results do not conclusively establish an increased intestinal cancer risk for DRA mutation carriers, they warrant further investigation.
- Further studies are recommended to elucidate the potential role of the DRA gene in cancer development.